07. July 2017

Shanghai’s Party Secretary Visits Oasis Site of Boehringer Ingelheim BioChina

On 07 July 2017, Mr. Zheng Han, the Party Secretary of Shanghai visited our Oasis BioSite located in the city’s free trade zone (FTZ) . This event was another important milestone in our BioChina roadmap and our participation in the Marketing Authorization Holder (MAH) trial project, providing a legal basis for biopharmaceuticals contract manufacturing in China. Mr. Han called for unremitting efforts to establish the FTZ according to the highest international standards from all aspects, especially in the areas of innovative and cutting-edge technologies. As a pioneer, Boehringer Ingelheim is the first multi-national pharmaceutical company which establishes and operates clinical and commercial scale manufacturing capabilities for biopharmaceutical products in the FTZ and in China.

Mr. Han was welcomed by Mr. David Preston (BI China President & CEO) and Dr. Jiali Luo (Site Head, BI BioChina) who expressed their appreciation to the strong government support. They hosted a guided tour through our state-of-the-art facility manufacturing world-class quality biopharmaceutical products.

Mr. Han highly emphasized the milestones which BI BioChina has achieved, and committed continued government full support to the further development of BI’s Biopharmaceuticals Contract Manufacturing Business in China.